Ocugen Reported a $0.10 Net Loss Per Share in Q3; Research and Development Expenses Were $15.6 Million-To The Moon - Tiger Brokers Online Investing Community - To The Moon

18
Comment
Favorite

Ocugen Reported a $0.10 Net Loss Per Share in Q3; Research and Development Expenses Were $15.6 Million

GlobeNewswire2022-11-08

Ocugen(NASDAQ: OCGN) today reported financial results for the quarter ended September 30, 2022, and provided a general business update.

The Company’s cash, cash equivalents, and restricted cash totaled $101.6 million as of September 30, 2022, compared to $95.1 million as of December 31, 2021. The Company believes that its current cash and cash equivalents balance will enable it to fund its operations into Q4 2023. The Company had 216.7 million shares of common stock outstanding as of September 30, 2022.
Research and development expenses for the three months ended September 30, 2022, were $15.6 million compared to $6.3 million for the three months ended September 30, 2021. General and administrative expenses for the three months ended September 30, 2022, were $7.5 million compared to $4.5 million for the three months ended September 30, 2021.
Ocugen reported a $0.10 net loss per share for the three months ended September 30, 2022, compared to a $0.05 net loss per share for the three months ended September 30, 2021.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

18

Report

Comment

Zivcheah
·2022-11-08
O
Reply
2
Report
Fold Replies
- Zivcheah:
  O
  2022-11-08
  Reply
  Report
cHao7
·2022-11-08
ok
Reply
1
Report
Fold Replies
- cHao7:
  k
  2022-11-21
  Reply
  Report
- cHao7:
  k
  2022-11-18
  Reply
  Report
- Thengz:
  Ok
  2022-11-08
  Reply
  Report
View more 1 comments

Most Discussed

7x24

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2281098999?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-11-08 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2281098999","market":"us","top_or_hot":-1,"title":"Ocugen Reported a $0.10 Net Loss Per Share in Q3; Research and Development Expenses Were $15.6 Million","media":"GlobeNewswire","content":"<html><head></head><body><p>Ocugen(NASDAQ: OCGN) today reported financial results for the quarter ended September 30, 2022, and provided a general business update.</p><ul><li>The Company’s cash, cash equivalents, and restricted cash totaled $101.6 million as of September 30, 2022, compared to $95.1 million as of December 31, 2021. The Company believes that its current cash and cash equivalents balance will enable it to fund its operations into Q4 2023. The Company had 216.7 million shares of common stock outstanding as of September 30, 2022.</li><li>Research and development expenses for the three months ended September 30, 2022, were $15.6 million compared to $6.3 million for the three months ended September 30, 2021. General and administrative expenses for the three months ended September 30, 2022, were $7.5 million compared to $4.5 million for the three months ended September 30, 2021.</li><li>Ocugen reported a $0.10 net loss per share for the three months ended September 30, 2022, compared to a $0.05 net loss per share for the three months ended September 30, 2021.</li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Reported a $0.10 Net Loss Per Share in Q3; Research and Development Expenses Were $15.6 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Reported a $0.10 Net Loss Per Share in Q3; Research and Development Expenses Were $15.6 Million\n</h2>\n\n<h4 class=\"meta\">\n\n2022-11-08 21:01 北京时间&nbsp;&nbsp;&nbsp;<strong>GlobeNewswire</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen(NASDAQ: OCGN) today reported financial results for the quarter ended September 30, 2022, and provided a general business update.The Company’s cash, cash equivalents, and restricted cash totaled...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":"","article_id":"2281098999","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2281098999","pubTimestamp":1667912502,"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"Ocugen(NASDAQ: OCGN) today reported financial results for the quarter ended September 30, 2022, and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen"},"translate_title":"Ocugen报告第三季度每股净亏损0.10美元；研究和开发费用为1560万美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":1},"content_text":"Ocugen(NASDAQ: OCGN) today reported financial results for the quarter ended September 30, 2022, and provided a general business update.The Company’s cash, cash equivalents, and restricted cash totaled $101.6 million as of September 30, 2022, compared to $95.1 million as of December 31, 2021. The Company believes that its current cash and cash equivalents balance will enable it to fund its operations into Q4 2023. The Company had 216.7 million shares of common stock outstanding as of September 30, 2022.Research and development expenses for the three months ended September 30, 2022, were $15.6 million compared to $6.3 million for the three months ended September 30, 2021. General and administrative expenses for the three months ended September 30, 2022, were $7.5 million compared to $4.5 million for the three months ended September 30, 2021.Ocugen reported a $0.10 net loss per share for the three months ended September 30, 2022, compared to a $0.05 net loss per share for the three months ended September 30, 2021.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":9987236620,"gmtCreate":1667915763560,"gmtModify":1676537984018,"author":{"id":"3582538202393061","authorId":"3582538202393061","name":"Zivcheah","avatar":"https://static.tigerbbs.com/d52882be9b594ebb5b5933851792d286","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9987236620","repostId":2281098999,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104714648,"gmtCreate":1667915769086,"gmtModify":1667915782194,"authorId":3582538202393061,"author":{"id":3582538202393061,"authorId":3582538202393061,"name":"Zivcheah","avatar":"https://static.tigerbbs.com/d52882be9b594ebb5b5933851792d286","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9987236620,"type":1,"supId":0,"prevId":0,"content":"<u>O</u>","text":"<u>O</u>","html":"<u>O</u>"}],"langContent":"EN"},{"id":9987293920,"gmtCreate":1667912835960,"gmtModify":1676537983359,"author":{"id":"3571630433284403","authorId":"3571630433284403","name":"cHao7","avatar":"https://static.tigerbbs.com/3800b5d66328f3184368a219227b02a3","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/9987293920","repostId":2281098999,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104899525,"gmtCreate":1669022862165,"gmtModify":1669022875770,"authorId":3571630433284403,"author":{"id":3571630433284403,"authorId":3571630433284403,"name":"cHao7","avatar":"https://static.tigerbbs.com/3800b5d66328f3184368a219227b02a3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9987293920,"type":1,"supId":104714146,"prevId":0,"content":"<u>k</u>","text":"<u>k</u>","html":"<u>k</u>"},{"id":104860557,"gmtCreate":1668766558182,"gmtModify":1668766571261,"authorId":3571630433284403,"author":{"id":3571630433284403,"authorId":3571630433284403,"name":"cHao7","avatar":"https://static.tigerbbs.com/3800b5d66328f3184368a219227b02a3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9987293920,"type":1,"supId":104715972,"prevId":0,"content":"<u>k</u>","text":"<u>k</u>","html":"<u>k</u>"},{"id":104715972,"gmtCreate":1667921329971,"gmtModify":1667921339958,"authorId":3579207760920564,"author":{"id":3579207760920564,"authorId":3579207760920564,"name":"Thengz","avatar":"https://static.tigerbbs.com/eb87a2ba614bf594d49c299bab92466e","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.48%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9987293920,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"},{"id":104714146,"gmtCreate":1667912873568,"gmtModify":1667912886641,"authorId":3571630433284403,"author":{"id":3571630433284403,"authorId":3571630433284403,"name":"cHao7","avatar":"https://static.tigerbbs.com/3800b5d66328f3184368a219227b02a3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9987293920,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":18,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}